Department of Pulmonary Medicine, Faculty of Medicine, Ondokuz Mayis University, Samsun, Turkey.
Ondokuz Mayıs Üniversitesi Göğüs Hst, 55139, Samsun, Turkey.
Infection. 2022 Jun;50(3):747-752. doi: 10.1007/s15010-021-01751-1. Epub 2022 Jan 4.
Vaccination is the most efficient way to control the coronavirus disease 2019 (COVID-19) pandemic, but vaccination rates remain below the target level in most countries. This multicenter study aimed to evaluate the vaccination status of hospitalized patients and compare two different booster vaccine protocols.
Inoculation in Turkey began in mid-January 2021. Sinovac was the only available vaccine until April 2021, when BioNTech was added. At the beginning of July 2021, the government offered a third booster dose to healthcare workers and people aged > 50 years who had received the two doses of Sinovac. Of the participants who received a booster, most chose BioNTech as the third dose.
We collected data from 25 hospitals in 16 cities. Patients hospitalized between August 1 and 10, 2021, were included and categorized into eight groups according to their vaccination status.
We identified 1401 patients, of which 529 (37.7%) were admitted to intensive care units. Nearly half (47.8%) of the patients were not vaccinated, and those with two doses of Sinovac formed the second largest group (32.9%). Hospitalizations were lower in the group which received 2 doses of Sinovac and a booster dose of BioNTech than in the group which received 3 doses of Sinovac.
Effective vaccinations decreased COVID-19-related hospitalizations. The efficacy after two doses of Sinovac may decrease over time; however, it may be enhanced by adding a booster dose. Moreover, unvaccinated patients may be persuaded to undergo vaccination.
接种疫苗是控制 2019 年冠状病毒病(COVID-19)大流行的最有效方法,但大多数国家的疫苗接种率仍低于目标水平。这项多中心研究旨在评估住院患者的接种状况,并比较两种不同的加强疫苗方案。
土耳其于 2021 年 1 月中旬开始接种疫苗。在 2021 年 4 月之前,只有科兴疫苗可用,之后加入了 BioNTech。2021 年 7 月初,政府向医护人员和接种两剂科兴疫苗的年龄>50 岁的人群提供了第三剂加强针。在接种加强针的人群中,大多数人选择 BioNTech 作为第三剂。
我们从土耳其 16 个城市的 25 家医院收集数据。将 2021 年 8 月 1 日至 10 日期间住院的患者纳入研究,并根据其接种状况将其分为 8 组。
我们共确定了 1401 名患者,其中 529 名(37.7%)患者入住重症监护病房。近一半(47.8%)的患者未接种疫苗,接种两剂科兴疫苗的患者构成第二大群体(32.9%)。接种两剂科兴疫苗和一剂 BioNTech 加强针的患者住院率低于接种三剂科兴疫苗的患者。
有效的疫苗接种降低了 COVID-19 相关的住院率。接种两剂科兴疫苗后的有效性可能会随时间推移而降低,但通过增加加强针剂量可能会增强其效果。此外,未接种疫苗的患者可能会被说服进行接种。